Bemiparin: Second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 6, 2008, Pages 793-802

  Martínez González, José ^a   Vila, Luis ^a   Rodríguez, Cristina ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Bemiparin; Deep venous thrombosis; Low molecular weight heparin; Prophylaxis; Pulmonary embolism; Treatment; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; BADYKET; BEMIPARIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPADREN; HEPARIN; IVOR; IVORAT; IVORMAX; NADROPARIN; PLACEBO; REVIPARIN; TINZAPARIN; UNCLASSIFIED DRUG; ZIBOR; FACTOR IIA; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING DISORDER; BONE DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEALTH CARE COST; HEMODIALYSIS; HUMAN; ORTHOPEDIC SURGERY; PROTHROMBIN TIME; SINGLE DRUG DOSE; THROMBOSIS PREVENTION; TOTAL KNEE REPLACEMENT; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM; COST BENEFIT ANALYSIS; DRUG ANTAGONISM; HALF LIFE TIME; RANDOMIZED CONTROLLED TRIAL; REVIEW;

COST-BENEFIT ANALYSIS; FACTOR XA; FIBRINOLYTIC AGENTS; HALF-LIFE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PROTHROMBIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOEMBOLISM;

EID: 48249113988     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.6.793     Document Type: Article

References (39)

1. Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur. J. Vasc. Endovasc. Surg. 25(1), 1-5 (2003).
2. McKelvie PA. Autopsy evidence of pulmonary thromboembolism. Med. J. Aust. 160(3), 127-128 (1994).
3. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl.), S338-S400 (2004).
4. Segal JB, Streif MB, Hofmann LV, Thornton K, Bass EB. Management of venous thromboembolism: a systematic review for a practice guideline. Ann. Intern. med. 146(3), 211-222 (2007).
5. Antman EM, Morrow DA, McCabe CH et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N. Engl. J. Med. 354(14), 1477-1488 (2006).
6. Lee S, Gibson CM. Enoxaparin in acute coronary syndromes. Expert Rev. Cardiovasc. Ther. 5(3), 387-399 (2007).
7. Iorio A. Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J. Thromb. Haemost. 1(9), 1906-1913 (2003).
8. Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349(2), 146-153 (2003).
9. Baglin T, Barrowcliffe TW, Cohen A et al. Guidelines on the use and monitoring of heparin. Br. J. Haematol. 133(1), 19-34 (2006).
10. Planès A. Review of bemiparin sodium - a new second-generation low molecular weight heparin and its applications in venous thromboembolism. Expert Opin. Pharmacother. 4(9), 1551-1561 (2003).
11. García Frade LJ, Peñarrubia Ponce MJ. Chemical structure-activity ratio of the low molecular weight heparins (HBPM). Towards a second generation of low molecular weight heparins? Rev. Iberoamer. Tromb. Hemostasia 13, 7-13 (2000).
12. Rocha E, Imberd D, Paschina E. Low-molecular-weight hepatitis: before or after surgery? New concepts and evidence: Congress report from the Sigma Tau/ROVI Satellite Symposium (Rome, Italy, 13 November 2006). Clin. Drug Investig. 27(5), 357-366 (2007).
13. Chapman TM, Goa KL. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis. Drugs 63(21), 2357-2377 (2003).
14. Depasse F, González de Suso MJ, Lagoutte I, Fontcuberta J, Borrell M, Samama MM. Comparative study of the pharmacokinetic profiles of two LMWH-bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)-administered subcutaneously to healthy male volunteers. Thromb. Res. 109(2-3), 109-117 (2003).
15. Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J. Thromb. Haemost. 5(5), 955-962 (2007).
16. Bates SM, Weitz JI. The status of new anticoagulants. Br. J. Haematol. 134(1), 3-19 (2006).
17. Christidou FN, Frangia TK, Bamichas GI et al. Comparison of two low-molecular weight heparins (LMV/H), tinzaparin and bemiparin, during hemodialysis. Int. J. Clin. Pharmacol. Ther. 43(7), 335-338 (2005).
18. Borrell M, Antonijoan RM, Ortiz R et al. Pharmacokinetic profile of two LMWH: bemiparin 3500 IU and enoxaparin 4000 IU after sc administration in healthy volunteers (18th Congress of the International Society of Thrombosis and Haemostasis. Paris, France, 2001). Thromb. Haemost. 86(Suppl.), CD3578 (2001).
19. Hoppensteadt DA, Jeske W, Fareed J, Bermes EW Jr. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul. Fibrinolysis. 6(Suppl. 1), S57-S64 (1995).
20. Falkon L, Garí M, Sáenz-Campos D, Antonijoan R, Barbanoj M, Fontcuberta J. Kinetic behaviour of the TFPI and anti-FXa effects, after the injection of a LMWH(RO- 11) in healthy subjects. Thromb. Haemost. 73(4), 728-729 (1995).
21. Falkon L, Garf M, Barbanoj M, Amiral J, Fontcuberta J. Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic sc doses. Blood Coagul. Fibrinolysis 9(2), 137-141 (1998).
22. Kakkar W, Howes J, Sharma V, Kadziola Z; The Bemiparin Assessment group. A comparative, double-blind, randomized trial of a new second generation LMWH (Bemiparin) and UFH in the prevention of post-operative venous thromboembolism. Thrumb. Haemost. 83, 523-529 (2000).
23. Navarro-Quilis A, Castellet E, Rocha E et al. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. J. Thromb. Haemost. 1(3), 425-432 (2003).
24. Honorato J, Gómez-Outes A, Navarro-Quilis X-Martínez-González J, Rocha E, Planès A. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous; thromboembolism in total knee replacement surgery. Pharmacoeconomics 22(13), 885-894 (2004).
25. Abad JI, Gómez-Outes A, Martínez-González J et al. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery. Arch. Orthop. Trauma Surg. 127(8), 665-670 (2007).
26. Otero-Fernández R, Gómez-Outes A, Martínez-González J et al. Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal chnical practice. Clin. Appl. Thromb. Hemost. 14(1), 75-83 (2008).
27. Balibrea JL, Altimiras J, Larruzea I et al. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice. Int J. Surg. 5(2), 114-119 (2007).
28. Constans M, Santamaria. A, Mateo J, Pujol N, Souto JC, Fontcuberta J. Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy. Int. J. Clin. Pract. 61(2), 212-217 (2007).
29. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arrh. Intern. Med. 164(12), 1319-1326 (2004).
30. Spyropoulos AC, Turpie AG. Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation. Curr. Opin. Pulm. Med. 11 (5), 373-379 (2005).
31. Miras-Parra F, Navascués-Martínez E, Gómez-Outes A et al. Utilisation and safety of bemiparin, a low-molecular-weight heparin, in medical patients: a prospective, uncontrolled cohort study. Clin. Drug Investig. 25(7), 463-472 (2005).
32. Pritto Seva AJ. Safety and effectiveness of bemiparin in the prevention of venous thromboembolic disease in nursing home patients. Rev. Esp. Geriatr. Gerontol. 42, 20-26 (2007).
33. Rodríguez-Mañas L, Gómez-Huelgas R, Monteagudo G, Maeso R, Gómez-Outes A, Martínez-González J. Bemiparin thromboprophylaxis in elderly medical patients: the "ANCIANOS" study. J. Thromb. Haemost. 5(Suppl. 2), P-T-671 (2007).
34. Kakkar W, Gebska M, Kadziola Z et al. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb. Haemost. 89(4), 674-680 (2003).
35. Gómez-Outes A. Rocha E, Martínez-González J, Kakkar VV. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis. Pharmacoeconomics 24(1), 81-92 (2006).
36. Santamaría A, Juárez S, Reche A et. al. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study. Int. J. Clin. Pract. 60(5), 518-525 (2006).
37. Lecumberri R, Rosario E, Pacho J, Rocha E; FLEBUS Investigators. Fixed-dose low-molecular-weight heparin, bemiparin, in the long-term treatment of venous thromboembolism in patients with transient risk factors in standard clinical practice: the FLEBUS study. J. Thromb. Haemost. 4(11), 2504-2508 (2006).
38. Ong BS, Karr MA, Chan DK, Frankel A, Shen Q. Management of pulmonary embolism in the home. Med. J. Aust. 183(5), 239-242 (2005).
39. Siragusa S, Arcara C, Malato A et al. Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Ann. Oncol. 16(Suppl. 4), iv136-iv139 (2005).